Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

Multi-platform reassessment of human mitochondrial DNA methylation reveals signals consistent with technical artifacts.

bioRxiv : the preprint server for biology·2026
Same author

Elevated mitochondrial protein import in acute myeloid leukemia increases reliance on mitochondrial protease LONP1.

The Journal of clinical investigation·2026
Same author

Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.

Nature communications·2026
Same author

Ex vivo expansion of hematopoietic stem and progenitor cells from human mobilized peripheral blood for gene therapy applications.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Related Experiment Video

Updated: Jul 26, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.2K

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.

Jaeseung C Kim1,2,3, Michelle Chan-Seng-Yue1, Sabrina Ge1,3

  • 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Nature Genetics
|June 19, 2023
PubMed
Summary
This summary is machine-generated.

Treatment resistance in BCR-ABL1 lymphoblastic leukemia is linked to B-cell maturation arrest. Early arrest causes poor outcomes, while late arrest leads to better remission rates with tyrosine kinase inhibitors (TKIs).

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

182

Related Experiment Videos

Last Updated: Jul 26, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.2K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

182

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Treatment heterogeneity to tyrosine kinase inhibitors (TKIs) in BCR-ABL1 lymphoblastic leukemia, particularly without kinase domain mutations, remains poorly understood.
  • Understanding the molecular drivers of differential TKI response is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the molecular basis of treatment heterogeneity in BCR-ABL1 lymphoblastic leukemia.
  • To identify distinct molecular subtypes and their correlation with clinical outcomes and TKI efficacy.

Main Methods:

  • Deep molecular profiling of BCR-ABL1 lymphoblastic leukemia patient samples.
  • Transcriptomic subtyping to classify leukemia based on B-cell progenitor differentiation stages.
  • Genomic event analysis to identify specific alterations associated with each subtype.

Main Results:

  • Three transcriptomic subtypes of BCR-ABL1 lymphoblastic leukemia were identified, corresponding to distinct B-cell progenitor maturation arrest stages.
  • Earlier maturation arrest correlated with lineage promiscuity, treatment refractoriness, and poor patient outcomes.
  • Later maturation arrest correlated with lineage fidelity, durable remissions, and improved patient outcomes.
  • Specific genomic events marked each maturation arrest stage and were absent in preleukemic stem cells, indicating downstream determination of transcriptomic phenotypes.

Conclusions:

  • Leukemia transformation at different B-cell differentiation stages dictates treatment response and TKI efficacy.
  • Transcriptomic subtypes provide a framework for understanding and potentially predicting TKI response in BCR-ABL1 lymphoblastic leukemia.
  • Targeting differentiation pathways may offer novel therapeutic strategies.